You searched for HTA - Page 2 of 29

We found for

Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures

Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?

Additional Elements of Value for Health Technology Assessment Decisions

How can HTA meet the needs of health system and government decision makers?

Transferability of HTA

HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers?

Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value

Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Uncertainty and Risk in HTA Decision Making

How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?

01
02
03
04

News & Insights

Latest Research & Publications

All Publications

We found for

Filter results by

Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Early Experience with Health Technology Assessment of Gene Therapies in the United States: Pricing and Paying for Cures

Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Antimicrobials Resistance: A Call for Multi-disciplinary Action. How Can HTA Help?

Additional Elements of Value for Health Technology Assessment Decisions

How can HTA meet the needs of health system and government decision makers?

Transferability of HTA

HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers?

Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value

Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?

Extrapolation from Progression-Free Survival to Overall Survival in Oncology

Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)

Uncertainty and Risk in HTA Decision Making

How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?